11β-hsd-1-in-1

11β-HSD1-IN-1 is an inhibitor of 11β-hydroxydehydrogenase 1 (11β-HSD1, IC50: 52 nM) used for the treatment of pain.

HSD-016 is an orally active, selective and potent type 1 11β-hydroxysteroid dehydrogenase (11β-HSD1) inhibitor with strong inhibitory effects on human, mouse and rat 11β-HSD1.HSD-016 can be used in the study of diabetes and metabolic syndrome.

11β-HSD1-IN-6 is a potent inhibitor of 11β hydroxysteroid dehydrogenase enzymes (11β-HSDs), which catalyze the conversion of active glucocorticoids, corticosterone or cortisol, to their inactive forms, 11-dehydrocorticosterone (11-DHC) and cortisone. The compound specifically targets and inhibits 11β-HSD-1, modulating the interconversion of these glucocorticoids. [1]

Morolic acid and moronic acid have shown sustained antidiabetic and antihyperglycemic action possibly mediated by an insulin sensitization with consequent changes of glucose, cholesterol and triglycerides, in part mediated by inhibition of 11β-HSD 1. Moro

Moronic acid shows oral therapeutic efficacy in HSV-infected mice and possessed novel anti-HSV activity. It also shows significant anti-HIV activity (EC(50) 186) and was modified to develop more potent anti-AIDS agents. Moronic acid is a new structural lead for anti-EBV drug development, can substantially reduce the numbers of EBV particles produced by the cells after lytic induction. Morolic and moronic acids have shown sustained antidiabetic and antihyperglycemic action possibly mediated by an insulin sensitization with consequent changes of glucose, cholesterol and triglycerides, in part mediated by inhibition of 11β-HSD 1 as indicated by in vitro.